Pricing
  1. US-listed companies
  2. SELLAS Life Sciences Group, Inc.
  3. Financials
  4. Cash from financing

SELLAS Life Sciences Group, Inc. (SLS)

Market cap
$552.77M
P/E ratio
SummaryFinancials
Period EndCash from financing (Million USD)YoY (%)
Dec 31, 202447+109.54%
Dec 31, 202322-7.33%
Dec 31, 202224+99.43%
Dec 31, 202112-68.59%
Dec 31, 202038+96.44%
Dec 31, 201920-15.37%
Dec 31, 201823+317.84%
Dec 31, 20176-83.88%
Dec 31, 201634-21.72%
Dec 31, 201544+80.73%
Dec 31, 201424-56.62%
Dec 31, 201356-50.68%
Dec 31, 2012113+59.78%
Dec 31, 201171

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat